- Email: [email protected]
Quality of life (QoL) improvements in 1464 patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X) in Brazil: implications for oncology nurses
ARTICLE IN PRESS ABSTRACTS women with breats cancer, to se if there are any similarities or differences to consider in the nursing care of these women. Conclusion: These results will hopefully increase healthcare professionals‘ understanding and knowledge of how postmenopausal women with diagnosed breast cancer and receiving adjuvant chemotherapy experience their time of treatment and the impact it has on their lives. With this knowledge, we can better assist and help the women and her family to cope with this difficult time. 10.1016/j.ejon.2006.04.029
Quality of life (QoL) improvements in 1464 patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X) in Brazil: Implications for oncology nurses ´alvesc, C. Testaa, F. Martinsb, D. GonA d e C. Huttener , O. Aguiar , A. Oliveiraf, C. Pereirag, N. Soffiattih, R. Ferroi, L. Zamprognaj a
Instituto Brazileiro de Controle do Cancer, Sao Paulo, Brazil b Hospital do Cancer—Instituto do Cancer do Ceara, Fortaleza, Brazil c Hospital Amaral Carvalho—Ja; Ja; Brazil d Hospital Escola da Fau—Pelotas, Pelotas, Brazil e Centro de Quimioterapia A. Imunoterapia—MG, Belo Horizonte, Brazil f Associacao Hospital de Caridade de IjuI´, IjuI´, Brazil g Real e Benemerita Sociedade Portuguesa de Beneficencia, S,o Paulo, Brazil h Hospital das Clinicas ˜ n Curitiba—Pr, Curitiba, Brazil i Sociedade Portuguesa de Beneficencia de Santos, Santos, Brazil j Hospital Sao Lucas PUCRS, Porto Alegre, Brazil Introduction: The oral fluoropyrimidine capecitabine is highly active and well tolerated as singleagent therapy and extends survival when added to docetaxel in pretreated MBC. Home-based therapy with oral X has a number of advantages over i.v. hospital-based regimens, including improvement in QoL and medical resource/cost savings vs. 5-FU/LV. However, treating patients with oral therapy requires a different approach to i.v. chemotherapy. Materials and methods: QoL was evaluated in women with anthracycline 7 taxane-pretreated MBC while receiving X (baseline, before cycle 1, at
229 weeks 7 and 13, and at treatment end) using EORTC QLQ C-30 (v3.0) and BR-23 questionnaires. We used linear models with repeated measures (generalized estimating questions technique) and SAS (v8.2) to determine improvement, stabilization or worsening of QoL scores from week 7 onwards. Each questionnaire item was analyzed as a function of patients ECOG status before first cycle and the evaluation periods. Results and discussion: Baseline characteristics of the 1464 evaluable patients were: median age 54 years (range 22-92); 42% had ECOG 0. As expected, patients with worse initial PS (ECOG 42) had lower mean scores during treatment. Regardless of baseline ECOG score, X therapy was associated with significant (Po0.0001 unless stated) improvements in pts’ perception of: role functioning (P ¼ 0.001), pain, nausea/vomiting, fatigue, constipation, emotional functioning, and global health status. Capecitabine was also associated with significant improvements in patients perception of systemic therapy side effects (Po0.0001), breast symptoms (Po0.0001), arm symptoms (P ¼ 0.0047), hair loss (Po0.0001), and future perspective (Po0.0001). These findings highlight the importance of considering QoL and other measurable benefits of oral treatments alongside well-established measures of clinical evaluation in pts with metastatic disease. Conclusion: Patients receiving X ray therapy had substantial improvements in almost all functional and symptomatic QoL domains. In order to ensure the effective management of patients receiving oral chemotherapy, oncology nurses need to play a more significant and pivotal role in the clinical oncology team. 10.1016/j.ejon.2006.04.030
Improvements in quality of life (QoL) in 1210 patients (pts) with metastatic colorectal cancer (MCRC) receiving capecitabine (X) in Brazil: Impact on oncology nursing D. Gonc-alvesa, L. Almeidab, M. Xarac, S. Nunesd, R. Ferroe, A. Oliveiraf, M. Vasquezg, O. Aguiarh, F. Martinsi, D. Cinij a
Hospital Amaral Carvalho—Jau, Ja; Brazil Instituto do Cancer Arnaldo Vieira Carvalho (ICAVC), Sao Paulo, Brazil c Hospital das Clinicas—Sao Paulo, Sao Paulo, Brazil d Hospital Erasto Gaertner—Curitiba, Curitiba, Brazil b
Quality of life (QoL) improvements in 1464 patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X) in Brazil: Implications for oncology nurses ´alvesc, C. Testaa, F. Martinsb, D. GonA d e C. Huttener , O. Aguiar , A. Oliveiraf, C. Pereirag, N. Soffiattih, R. Ferroi, L. Zamprognaj a
Instituto Brazileiro de Controle do Cancer, Sao Paulo, Brazil b Hospital do Cancer—Instituto do Cancer do Ceara, Fortaleza, Brazil c Hospital Amaral Carvalho—Ja; Ja; Brazil d Hospital Escola da Fau—Pelotas, Pelotas, Brazil e Centro de Quimioterapia A. Imunoterapia—MG, Belo Horizonte, Brazil f Associacao Hospital de Caridade de IjuI´, IjuI´, Brazil g Real e Benemerita Sociedade Portuguesa de Beneficencia, S,o Paulo, Brazil h Hospital das Clinicas ˜ n Curitiba—Pr, Curitiba, Brazil i Sociedade Portuguesa de Beneficencia de Santos, Santos, Brazil j Hospital Sao Lucas PUCRS, Porto Alegre, Brazil Introduction: The oral fluoropyrimidine capecitabine is highly active and well tolerated as singleagent therapy and extends survival when added to docetaxel in pretreated MBC. Home-based therapy with oral X has a number of advantages over i.v. hospital-based regimens, including improvement in QoL and medical resource/cost savings vs. 5-FU/LV. However, treating patients with oral therapy requires a different approach to i.v. chemotherapy. Materials and methods: QoL was evaluated in women with anthracycline 7 taxane-pretreated MBC while receiving X (baseline, before cycle 1, at
229 weeks 7 and 13, and at treatment end) using EORTC QLQ C-30 (v3.0) and BR-23 questionnaires. We used linear models with repeated measures (generalized estimating questions technique) and SAS (v8.2) to determine improvement, stabilization or worsening of QoL scores from week 7 onwards. Each questionnaire item was analyzed as a function of patients ECOG status before first cycle and the evaluation periods. Results and discussion: Baseline characteristics of the 1464 evaluable patients were: median age 54 years (range 22-92); 42% had ECOG 0. As expected, patients with worse initial PS (ECOG 42) had lower mean scores during treatment. Regardless of baseline ECOG score, X therapy was associated with significant (Po0.0001 unless stated) improvements in pts’ perception of: role functioning (P ¼ 0.001), pain, nausea/vomiting, fatigue, constipation, emotional functioning, and global health status. Capecitabine was also associated with significant improvements in patients perception of systemic therapy side effects (Po0.0001), breast symptoms (Po0.0001), arm symptoms (P ¼ 0.0047), hair loss (Po0.0001), and future perspective (Po0.0001). These findings highlight the importance of considering QoL and other measurable benefits of oral treatments alongside well-established measures of clinical evaluation in pts with metastatic disease. Conclusion: Patients receiving X ray therapy had substantial improvements in almost all functional and symptomatic QoL domains. In order to ensure the effective management of patients receiving oral chemotherapy, oncology nurses need to play a more significant and pivotal role in the clinical oncology team. 10.1016/j.ejon.2006.04.030
Improvements in quality of life (QoL) in 1210 patients (pts) with metastatic colorectal cancer (MCRC) receiving capecitabine (X) in Brazil: Impact on oncology nursing D. Gonc-alvesa, L. Almeidab, M. Xarac, S. Nunesd, R. Ferroe, A. Oliveiraf, M. Vasquezg, O. Aguiarh, F. Martinsi, D. Cinij a
Hospital Amaral Carvalho—Jau, Ja; Brazil Instituto do Cancer Arnaldo Vieira Carvalho (ICAVC), Sao Paulo, Brazil c Hospital das Clinicas—Sao Paulo, Sao Paulo, Brazil d Hospital Erasto Gaertner—Curitiba, Curitiba, Brazil b